Lalwani Nikhil sold $383K of ANIP

Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.

ANI Pharmaceuticals (ANIP) received FDA approval for its generic Everolimus Tablets for Oral Suspension in 2mg, 3mg, and 5mg strengths. The product, a generic version of Afinitor Disperz, expands ANI's generics portfolio. The company expects to launch at least 15 new generic products this year. U.S. annual sales for the approved product were approximately $123 million, according to IQVIA data cited by ANI. ANIP's stock closed at $77.91 on Tuesday, with pre-market trading at $78.99.

ANI Pharmaceuticals (ANIP) appointed Henry Gosebruch to its board, replacing Muthusamy Shanmugam, who will remain in operational roles. Gosebruch has biotech leadership experience. The company, with a $1.6b market cap, develops and markets branded and generic drugs. Board changes may influence capital allocation and product mix.

ANI Pharmaceuticals (ANIP) reported Q2 and first-half 2026 results, reaffirming its net revenue outlook. The stock is down 0.90% in one day and 6.53% over 90 days, but up 176.54% over 5 years. The company is trading at $77.32, below a fair value estimate of $112.71, with growth potential in Cortrophin Gel and other rare disease products.

ANI Pharmaceuticals (ANIP) reported Q2 2026 earnings with total revenue of $266.0 million, up 25.9% YoY, driven by Rare Disease and Generics segments. Adjusted EBITDA rose 32.4% to $71.6 million, exceeding expectations. Cortrophin Gel revenue increased 43.5% to $117.1 million. The company reaffirmed full-year revenue guidance of $1.08B-$1.14B but lowered Cortrophin Gel outlook to $520M-$540M. Management highlighted progress in rare disease focus and sales force expansion.

ANI Pharmaceuticals reported Q2 2026 sales of $266.04 million and net income of $24.71 million, and reaffirmed full-year 2026 net revenue guidance of $1.08 billion to $1.14 billion, according to the company. The article links results to rare disease therapy Cortrophin Gel and the generics portfolio.